Filing Details
- Accession Number:
- 0001209191-23-046282
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-17 16:35:43
- Reporting Period:
- 2023-08-15
- Accepted Time:
- 2023-08-17 16:35:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1358762 | Reata Pharmaceuticals Inc | RETA | Pharmaceutical Preparations (2834) | 113651945 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1688712 | Carter Dawn Bir | 5320 Legacy Dr. Plano TX 75024 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Disposition | 2023-08-15 | 807 | $169.04 | 34,203 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2023-08-16 | 398 | $168.33 | 33,805 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $169.00 to $169.06. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $168.28 to $168.49. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.